Diatrizoate Sodium
A sodium salt of the iodinated contrast agent diatrizoate, used in radiological imaging procedures such as urography, venography, and CT scans to make blood vessels, organs, and body cavities visible on X-ray images. The iodine atoms absorb X-rays, creating contrast between structures. It can cause allergic reactions and kidney damage, particularly in patients with existing kidney problems.
Masse moléculaire
635,8900 g/mol
TPSA
98,30 Ų
Aires thérapeutiques
Mécanisme d'action
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Pharmacokinetics (PK)
Pharmacodynamics (PD)
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Structure 2D
Cite this structure
Embed this structure
SMILES
CC(=O)Nc1c(I)c(NC(C)=O)c(I)c(C(=O)[O-])c1I.[Na+]
InChI
InChI=1S/C11H9I3N2O4.Na/c1-3(17)15-9-6(12)5(11(19)20)7(13)10(8(9)14)16-4(2)18;/h1-2H3,(H,15,17)(H,16,18)(H,19,20);/q;+1/p-1
Molecular Formula
C11H8I3N2NaO4
HBD / HBA
2 / 4
Liaisons Rotatives
3
Atomes Lourds
21
No targets recorded
Target interaction data is not yet available for this drug.
No interactions recorded
Drug interaction data is not yet available for this compound.
No side effects recorded
Side effect data is not yet available for this drug.
Foire aux questions
A sodium salt of the iodinated contrast agent diatrizoate, used in radiological imaging procedures such as urography, venography, and CT scans to make blood vessels, organs, and body cavities visible on X-ray images. The iodine atoms absorb X-rays, creating contrast between structures. It can cause allergic reactions and kidney damage, particularly in patients with existing kidney problems.
Enhances the contrast of specific tissues or structures during medical imaging procedures by altering the local signal intensity or X-ray absorption characteristics.
Yes, Diatrizoate Sodium is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.
References & Data Sources
- ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200581. Open-access bioactivity database.
- PubChem — National Center for Biotechnology Information (NCBI). CID 23672589. Chemical information database.
Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.
Embed This Widget
Add the script tag and a data attribute to embed this widget.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<div data-drugfyi="drug" data-slug="diatrizoate-sodium"></div>Embed via iframe for maximum compatibility.
<iframe src="https://drugfyi.com/iframe/drug/diatrizoate-sodium/" width="420" height="400" frameborder="0" style="border:0;border-radius:10px;max-width:100%" loading="lazy"></iframe>Paste this URL in WordPress, Medium, or any oEmbed-compatible platform.
https://drugfyi.com/drug/diatrizoate-sodium/Add a dynamic SVG badge to your README or docs.
[](https://drugfyi.com/drug/diatrizoate-sodium/)Use the native HTML custom element.
<script src="https://cdn.jsdelivr.net/npm/drugfyi-embed@1/dist/embed.min.js" defer></script>
<drugfyi-drug slug="diatrizoate-sodium"></drugfyi-drug>